A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors

The PI3K/Akt/mTOR signaling pathway is aberrantly activated in various pediatric tumors. We conducted a phase I study of the Akt inhibitor perifosine in patients with recurrent/refractory pediatric CNS and solid tumors. This was a standard 3+3 open-label dose-escalation study to assess pharmacokinet...

Descripción completa

Detalles Bibliográficos
Autores principales: Becher, Oren J., Millard, Nathan E., Modak, Shakeel, Kushner, Brian H., Haque, Sofia, Spasojevic, Ivan, Trippett, Tanya M., Gilheeney, Stephen W., Khakoo, Yasmin, Lyden, David C., De Braganca, Kevin C., Kolesar, Jill M., Huse, Jason T., Kramer, Kim, Cheung, Nai-Kong V., Dunkel, Ira J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5459446/
https://www.ncbi.nlm.nih.gov/pubmed/28582410
http://dx.doi.org/10.1371/journal.pone.0178593

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5459446/
https://www.ncbi.nlm.nih.gov/pubmed/28582410
http://dx.doi.org/10.1371/journal.pone.0178593

Ejemplares similares